Focusing on uncommon and underserved medical conditions, Genzyme's Rare Disease business unit develops breakthrough therapies for patients who might otherwise have few treatment options.
Brendan Martin, General Manager, Genzyme UK and Ireland talks about their involvement in Rare Disease Day and the work they are doing to improve the lives of patients with rare diseases.
Focusing on uncommon and underserved medical conditions, Genzyme's Rare Disease business unit develops breakthrough therapies for patients who might otherwise have few treatment options. Brendan Martin, General Manager, Genzyme UK and Ireland talks about their involvement in Rare Disease Day and the work they are doing to improve the lives of patients with rare diseases.
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Corporate Overview Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. We've kept our roots in the Boston area: our headquarters, Genzyme Center, is located in Cambridge, Massachusetts, home to venerable universities, teaching hospitals, and a thriving biotechnology community. But we also operate in every other region of the globe. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before.